Recent results from Total Therapy Study X for standard and high risk acute lymphoblastic leukemia in children: recognition of new clinical and biologic risk features.
Recent results from Total Therapy Study X for standard and high risk acute lymphoblastic leukemia in children: recognition of new clinical and biologic risk features.
复制标题
针对儿童标准和高风险急性淋巴细胞白血病的总体治疗研究 X 的最新结果：认识到新的临床和生物学风险特征。
DOI：
10.1007/978-3-642-70385-0_19
复制
发表时间：
1985
期刊：
影响因子：
--
通讯作者：
Evans,WE
中科院分区：
文献类型：
--
作者：
Murphy,SB;Dahl,GV;Look,AT;Ochs,J;Abromowitch,M;Pui,CH;Bowman,WP;Simone,JV;Kalwinsky,DK;Evans,WE
1979年全面治疗研究X的启动标志着圣犹达白血病研究的重要新方向，因为标准淋巴细胞白血病和高风险淋巴细胞白血病的治疗方法首次出现根本不同。此外，考虑到儿童ALL的异质性，我们采用标准方法前瞻性研究了每位新患者的母细胞特征[1-3]，并深入研究了各种临床和生物学特征对治疗结果的独立影响。本报告将重点介绍我们最近取得的成果。
The initiation of Total Therapy Study X in 1979 marked important new directions for leukemia studies at St. Jude, since for the first time treatment for standard and high risk forms of lymphoblastic leukemia differed radically. Furthermore, recognizing the heterogeneity of childhood ALL, the blast cell characteristics of each new patient were prospectively investigated by standard methods [1-3], and the independent impact of various clinical and biologic features on the outcome of therapy was thoroughly investigated. This report will present highlights of our recent results.